Integrated BioPharma Q1 revenue up 4.9% to $12.9M; net loss widens to $59K

INTEGRATED BIOPHARMA INC

2025-Q1 EPS reported $0.00 revenue$12,915,000

Revenue $12.9M vs $12.3M YoY, a 4.9% increase.
Operating loss of $54K vs operating income of $30K in prior year.
Net loss of $59K ($0.00 per share) vs net loss of $35K ($0.00 per share).
Two largest customers represent 91% of Q1 revenue in Contract Manufacturing Segment.
Co-CEOs cite revenue growth from top customers.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

INTEGRATED BIOPHARMA INC reported the quarter ended September 30, 2023 results: revenue $12.9 million, net income net loss of approximately $59,000 or $0.00 per share, EPS $0.00 per share of common stock.

Period: the quarter ended September 30, 2023
Revenue: $12.9 million
Net income: net loss of approximately $59,000 or $0.00 per share
EPS: $0.00 per share of common stock
Result: reported results

Exact text from the filing

Inc. (OTCQX: INBP) (the “Company” or “INBP”) reports its financial results for the quarter ended September 30, 2023. Revenue for the quarter ended September 30, 2023 was $12.9 million compared to $12.3 million for the quarter ended September 30, 2022, an increase of $0.6 million or approximately 4.9%. The Company had an operating loss for the quarter ended

View on SEC.gov

Browse all earnings releases →

INTEGRATED BIOPHARMA INC filing history →

Source: SEC EDGAR

accession 0001437749-23-031188

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.